Caris Life Sciences Inc 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commissionfile number: 001-42706_________________________________________ CARIS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter)_________________________________________ 85-2077369 (I.R.S. Employer Identification Number) 750 W. John Carpenter FreewaySuite 800Irving, TX 75039(Address of principal executive offices, including ZIP code) Registrant’s telephone number, including area code: (866) 771-8946 Not applicable(Former name or former address, if changed since last report)_________________________________________ Securities registered pursuant to Section 12(b) of the Act: The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) hasfiled all reports required to befiled by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required tofile such reports),and (2) has been subject to suchfiling requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantwas required to submit suchfiles). Yes☒No☐ Indicate by check mark whether the registrant is a large acceleratedfiler, an acceleratedfiler, a non-acceleratedfiler, a smaller reportingcompany, or an emerging growth company. See the definitions of “large acceleratedfiler,” “acceleratedfiler,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large acceleratedfiler☐Acceleratedfiler☐Non-acceleratedfiler☒Smaller reporting company☐Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May5, 2026, the registrant had 282,680,695 shares of common stock, par value $0.001 per share, outstanding. CARIS LIFE SCIENCES, INC.FORM 10-Q TABLE OF CONTENTS Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of thePrivate Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical factscontained in this Quarterly Report, including statements regarding our expectations of future results of operations andfinancialcondition, business strategy, future solutions, and launches of new solutions, technology, R&D costs, regulatory approvals, potentialmarket opportunity, anticipated trends in our business, timing and likelihood of success, as well as plans and objectives of managementfor future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and otherimportant factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to bematerially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,”“predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions, are intended toidentify forward looking statements. Forward-looking statements contained in this Quarterly Report include, but are not limited to,statements about: •developments in the precision medicine industry, including the market size for molecular information services and ourbiopharma partners’ use of molecular information;•our expectations as to our addressable U.S. market in oncology, futurefinancial performance, results of operations, or otheroperational results or metrics;•our ability to scale the Caris platform and develop and successfully launch new solutions or enhancements to existing solutions,as well as commercial market acceptance for our solutions, acceptance of preventive as well as diagnostic testing paradigms,and our ability to generate and meet demand for new and enhanced solutions;•our ability to capture, aggregate, analyze, or otherwise utilize molecular information in novel ways;•our ability to compete with companies that are currently in, or may in the future enter, the industry in which we operate;•third-party pa